MA29787B1 - Traitement de maladies auto-immunes - Google Patents

Traitement de maladies auto-immunes

Info

Publication number
MA29787B1
MA29787B1 MA30758A MA30758A MA29787B1 MA 29787 B1 MA29787 B1 MA 29787B1 MA 30758 A MA30758 A MA 30758A MA 30758 A MA30758 A MA 30758A MA 29787 B1 MA29787 B1 MA 29787B1
Authority
MA
Morocco
Prior art keywords
autoimmune diseases
treatment
methods
sclerosis
ureity
Prior art date
Application number
MA30758A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29787B1 publication Critical patent/MA29787B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION PORTE SUR DES MÉTHODES DE TRAITEMENT DE DIVERSES MALADIES AUTO-IMMUNES, TELLES QUE LA SCLÉROSE EN PLAQUE, LA NÉVRITE PÉRIPHÉRIQUE, LA NÉVRITE OPTIQUE, LA SCLÉROSE AMYOTROPHIQUE LATÉRALE ET L'UVÉITE, CES MÉTHODES UTILISANT DES DÉRIVÉS AMINO-ALCOOL SPÉCIFIQUES.
MA30758A 2005-09-09 2008-03-17 Traitement de maladies auto-immunes MA29787B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
MA29787B1 true MA29787B1 (fr) 2008-09-01

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30758A MA29787B1 (fr) 2005-09-09 2008-03-17 Traitement de maladies auto-immunes

Country Status (29)

Country Link
US (1) US20080200438A1 (fr)
EP (2) EP1926483B1 (fr)
JP (4) JP5244598B2 (fr)
KR (3) KR20140117704A (fr)
CN (1) CN101257899B (fr)
AT (1) ATE489948T1 (fr)
AU (2) AU2006289100B2 (fr)
BR (1) BRPI0615906A2 (fr)
CA (2) CA2620554C (fr)
CY (1) CY1111285T1 (fr)
DE (1) DE602006018629D1 (fr)
DK (2) DK2295049T3 (fr)
ES (2) ES2529724T3 (fr)
HK (1) HK1149906A1 (fr)
IL (2) IL189665A (fr)
JO (1) JO2655B1 (fr)
MA (1) MA29787B1 (fr)
MX (1) MX2008003170A (fr)
NO (1) NO20081727L (fr)
NZ (2) NZ588372A (fr)
PL (2) PL2295049T3 (fr)
PT (2) PT1926483E (fr)
RU (2) RU2493840C2 (fr)
SG (1) SG165364A1 (fr)
SI (2) SI2295049T1 (fr)
TN (1) TNSN08103A1 (fr)
TW (2) TWI376223B (fr)
WO (1) WO2007028821A2 (fr)
ZA (1) ZA200801694B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4917433B2 (ja) * 2004-07-16 2012-04-18 杏林製薬株式会社 効果的な医薬の使用法及び副作用発現の防御に関する方法
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
EP1932522B1 (fr) * 2005-10-07 2012-05-23 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique destiné à une maladie du foie contenant un dérivé 2-amino-1,3-propanediol servant de principe actif
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RS53080B (en) * 2006-08-08 2014-06-30 Kyorin Pharmaceutical Co. Ltd. AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT
WO2008018447A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'aminoalcool et immunodépresseur le contenant en tant que principe actif
US20100093745A1 (en) * 2007-02-13 2010-04-15 Kazuhiko Kuriyama Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
RU2505288C2 (ru) * 2008-05-20 2014-01-27 Киорин Фармасьютикал Ко., Лтд. Средства поддержания индуцированной ремиссии
KR20110049870A (ko) * 2008-08-18 2011-05-12 노파르티스 아게 탈수초성 말초 신경병증의 치료를 위한 아미노 알콜 유도체
WO2011138393A1 (fr) * 2010-05-06 2011-11-10 Novartis Ag Traitement de maladies autoimmunes
MX2012012925A (es) * 2010-05-06 2012-12-17 Novartis Ag Regimen de dosificacion de derivados de sulfuro de diarilo.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
EP2030614A1 (fr) * 1997-02-27 2009-03-04 Novartis AG Composition pharmaceutique comprenant le 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol et une lécithine
DE60223699T2 (de) * 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
TWI376363B (en) * 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
CA2499882C (fr) * 2002-09-28 2010-11-09 Mcneil-Ppc, Inc. Formes posologiques a libration modifiee comportant deux noyaux
WO2004074297A1 (fr) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. Derives d'acide aminophosphonique, leurs sels d'addition et des modulateurs de recepteurs s1p
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
TW200505416A (en) * 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
PT1660449E (pt) * 2003-08-28 2010-01-21 Novartis Ag Derivados de aminopropanol
JP4917433B2 (ja) * 2004-07-16 2012-04-18 杏林製薬株式会社 効果的な医薬の使用法及び副作用発現の防御に関する方法
MX2007006373A (es) * 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ES2529724T3 (es) 2015-02-25
ES2357426T3 (es) 2011-04-26
HK1149906A1 (en) 2011-10-21
KR20080046231A (ko) 2008-05-26
RU2008113187A (ru) 2009-10-20
KR20140019033A (ko) 2014-02-13
RU2493840C2 (ru) 2013-09-27
US20080200438A1 (en) 2008-08-21
CA2620554C (fr) 2013-12-17
WO2007028821A2 (fr) 2007-03-15
WO2007028821A3 (fr) 2007-05-03
TWI372620B (en) 2012-09-21
NO20081727L (no) 2008-06-06
EP2295049B1 (fr) 2014-11-26
NZ566137A (en) 2011-05-27
CA2620554A1 (fr) 2007-03-15
TNSN08103A1 (en) 2009-07-14
SG165364A1 (en) 2010-10-28
ATE489948T1 (de) 2010-12-15
AU2010224355B2 (en) 2012-03-29
TW200803829A (en) 2008-01-16
SI1926483T1 (sl) 2011-04-29
RU2424795C2 (ru) 2011-07-27
EP2295049A1 (fr) 2011-03-16
EP1926483B1 (fr) 2010-12-01
CY1111285T1 (el) 2015-08-05
AU2010224355A1 (en) 2010-10-14
JP6077265B2 (ja) 2017-02-08
CN101257899B (zh) 2012-10-03
AU2006289100B2 (en) 2010-07-22
NZ588372A (en) 2012-03-30
CA2820510A1 (fr) 2007-03-15
JP2009507810A (ja) 2009-02-26
PT1926483E (pt) 2011-03-03
MX2008003170A (es) 2008-03-18
PL1926483T3 (pl) 2011-05-31
ZA200801694B (en) 2009-09-30
JP2017019854A (ja) 2017-01-26
RU2011111117A (ru) 2012-09-27
AU2006289100A1 (en) 2007-03-15
KR20140117704A (ko) 2014-10-07
SI2295049T1 (sl) 2015-03-31
TWI376223B (en) 2012-11-11
EP1926483A2 (fr) 2008-06-04
IL233328A0 (en) 2014-08-31
JP5244598B2 (ja) 2013-07-24
IL189665A0 (en) 2008-06-05
JO2655B1 (en) 2012-06-17
DK2295049T3 (en) 2015-02-23
DK1926483T3 (da) 2011-03-14
PL2295049T3 (pl) 2015-04-30
DE602006018629D1 (de) 2011-01-13
KR101476591B1 (ko) 2014-12-24
PT2295049E (pt) 2015-03-02
TW201034659A (en) 2010-10-01
IL189665A (en) 2014-07-31
KR101476451B1 (ko) 2014-12-24
CN101257899A (zh) 2008-09-03
JP2015025002A (ja) 2015-02-05
BRPI0615906A2 (pt) 2011-05-31
JP2013010802A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
MA29787B1 (fr) Traitement de maladies auto-immunes
BRPI0511875A (pt) uso de compostos de peptìdeo para tratamento da esclerose lateral amiotrófica
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
DE602004007808D1 (de) Neue gamma secretase inhibitoren
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
BRPI0408491A (pt) tratamento da doença de alzheimer
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
GB0606015D0 (en) therapeutic agents
EA200800890A1 (ru) Модуляторы гексагидроциклогептапиразол каннабиноида
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
UY27145A1 (es) Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil) etanol para tratar la incontinencia urinaria
BR0309110A (pt) composições e processo de tratamento da doença de alzheimer
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина